Except for in specific NHL subtypes and, potentially, when used in combination with CAR T-cell therapy, PD-1/PD-L1 ICIs typically provides limited additional clinical benefit when combined with other active treatments in R/R NHL. This evidence concerns the gene PDCD1 and non-Hodgkin lymphoma.